Table 1.
Baseline Anthropometrics, Clinical, and Physiologic Characteristics of the Patients Included in the Analysis
| Total (n = 14,497) | Observational (n = 8,423) | Pharmacologic (n = 4,856) | NETT (n = 1,218) | |
|---|---|---|---|---|
| Age, yr, mean (SD)* | 64 (9) | 64 (9) | 64 (9) | 67 (5) |
| Sex, females, n (%) | 4,867 (34) | 2,979 (35) | 1,416 (29) | 472 (39) |
| Race, nonwhite, n (%)* | 1,854 (13) | 1,070 (13) | 722 (15) | 62 (5) |
| Region of the world, n (%) | ||||
| Americas | 9,066 (62.5) | 6,157 (73.1) | 1,691 (34.8) | 1,218 (100.0) |
| European | 4,933 (34.0) | 2,230 (26.5) | 2,703 (55.7) | 0 (0.0) |
| Southeast Asia | 254 (1.8) | 0 (0.0) | 254 (5.2) | 0 (0.0) |
| Western Pacific | 165 (1.1) | 36 (0.4) | 129 (2.7) | 0 (0.0) |
| African | 79 (0.5) | 0 (0.0) | 79 (1.6) | 0 (0.0) |
| GOLD COPD spirometric severity, n (%)* | ||||
| 0 | 12 (0.1) | 12 (0.1) | 0 (0.0) | 0 (0.0) |
| 1 | 1,164 (8.2) | 1,051 (12.9) | 113 (2.4) | 0 (0.0) |
| 2 | 5,618 (39.7) | 3,204 (39.4) | 2,411 (50.3) | 3 (0.2) |
| 3 | 5,200 (36.7) | 2,714 (33.3) | 2,084 (43.5) | 402 (33.0) |
| 4 | 2,158 (15.2) | 1,161 (14.3) | 184 (3.8) | 813 (66.7) |
| Missing/unclassified | 345 (2.4) | 281 (3.3) | 64 (1.3) | 0 (0.0) |
| History of exacerbations in previous 12 mo, n (%)* | ||||
| 0 | 7,851 (71.3) | 3,937 (61.7) | 3,914 (84.7) | — |
| 1 | 1,819 (16.5) | 1,328 (20.8) | 491 (10.6) | — |
| 2 | 709 (6.4) | 605 (9.5) | 104 (2.2) | — |
| 3 or more | 628 (5.7) | 514 (8.15) | 114 (2.5) | — |
| Missing | 3,490 (24.1) | 2,039 (24.2) | 233 (4.8) | 1,218 (100) |
| Comorbidities, yes, n (%) | ||||
| Hypertension | 5,833 (45.8) | 3,872 (47.7) | 1,961 (42.4) | — |
| Cardiovascular | 2,483 (30.0) | 2,483 (30.0) | — | — |
| Diabetes | 1,469 (12.7) | 1,136 (13.6) | 333 (10.5) | — |
| 6MWD, m, mean (SD) | 366.5 (119.59) | 369.9 (123.64) | 360.1 (117.64) | 368.4 (95.45) |
Definition of abbreviations: 6MWD = 6-minute-walk distance; COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; NETT = National Emphysema Therapy Trial.
Some values were statistically significantly different but of limited clinical importance.
*
There were statistical differences among all groups (P < 0.05).